Brief: Clearside Biomedical Completes Dosing In Oasis Phase 1/2A Clinical Trial Of CLS-AX In Wet AMD Patients
26/07/2022 12:28
July 26 (Reuters) - Clearside Biomedical Inc CLSD.O :
* CLEARSIDE BIOMEDICAL COMPLETES DOSING IN OASIS PHASE 1/2A
CLINICAL TRIAL OF CLS-AX (AXITINIB INJECTABLE SUSPENSION) IN WET
AMD PATIENTS
* CLEARSIDE BIOMEDICAL INC - FINAL OASIS DATA EXPECTED IN Q4
2022
* CLEARSIDE BIOMEDICAL INC - CLS-AX DOSING COMPLETED IN
COHORTS 3
AND 4
Source text for Eikon: ID:nGNX3qkV2N
Further company coverage: CLSD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearside Biomedical,
See all newsBrief: Clearside Biomedical Completes Financial Restructuring And Emerges From Chapter 11 With Steel Partners As Plan Sponsor
U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
Clearside Biomedical plunges after filing for Chapter 11 bankruptcy
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials